Foramen ovale

Patent Foramen Ovale Closure Devices Market Expected to Rise at a CAGR of 3.1% by 2026, Affirms DelveInsight

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Circulatory system, Cardiovascular system, Cardiology, Foramen ovale, Obstetrics, Pediatrics, PFO, Cardiac surgery, Atrial septal defect, Barry A. Love

b"LAS VEGAS, April 21, 2021 /PRNewswire/ -- DelveInsight's' Patent Foramen Ovale Closure Devices- Market Insights, Competitive Landscape and Market Forecast -2026 'provides the current and forecast market of the Patent Foramen Ovale Closure Devices and comprises of market trends and key competitors of Patent Foramen Ovale Closure Devices.

Key Points: 
  • b"LAS VEGAS, April 21, 2021 /PRNewswire/ -- DelveInsight's' Patent Foramen Ovale Closure Devices- Market Insights, Competitive Landscape and Market Forecast -2026 'provides the current and forecast market of the Patent Foramen Ovale Closure Devices and comprises of market trends and key competitors of Patent Foramen Ovale Closure Devices.
  • DelveInsightestimated the market to grow at a steady CAGR over the study period of 2018 2026.\nKey Highlights of Patent Foramen Ovale Closure Devices Market report:\nPatent Foramen Ovale Closure Devices are minimally invasive devices that are used for the mechanical closure of the Patent Foramen Ovale.
  • In the year 2018, the total prevalent cases of selected indications for Patent Foramen Ovale Closure Devices were 51,434 cases in the 7MM, which might reach 53,250 cases by 2026.
  • On October 28, 2016, the FDA approved the Amplatzer PFO Occluder device for patients under a stroke risk due to PFO.

Patent Foramen Ovale Closure Devices Market Expected to Rise at a CAGR of 3.1% by 2026, Affirms DelveInsight

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Circulatory system, Cardiovascular system, Cardiology, Foramen ovale, Obstetrics, Pediatrics, PFO, Cardiac surgery, Atrial septal defect, Barry A. Love

b"- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible procedures globally.\nLAS VEGAS, April 21, 2021 /PRNewswire/ -- DelveInsight's' Patent Foramen Ovale Closure Devices- Market Insights, Competitive Landscape and Market Forecast -2026 'provides the current and forecast market of the Patent Foramen Ovale Closure Devices and comprises of market trends and key competitors of Patent Foramen Ovale Closure Devices.

Key Points: 
  • b"- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible procedures globally.\nLAS VEGAS, April 21, 2021 /PRNewswire/ -- DelveInsight's' Patent Foramen Ovale Closure Devices- Market Insights, Competitive Landscape and Market Forecast -2026 'provides the current and forecast market of the Patent Foramen Ovale Closure Devices and comprises of market trends and key competitors of Patent Foramen Ovale Closure Devices.
  • DelveInsightestimated the market to grow at a steady CAGR over the study period of 2018 2026.\nKey Highlights of Patent Foramen Ovale Closure Devices Market report:\nPatent Foramen Ovale Closure Devices are minimally invasive devices that are used for the mechanical closure of the Patent Foramen Ovale.
  • In the year 2018, the total prevalent cases of selected indications for Patent Foramen Ovale Closure Devices were 51,434 cases in the 7MM, which might reach 53,250 cases by 2026.
  • On October 28, 2016, the FDA approved the Amplatzer PFO Occluder device for patients under a stroke risk due to PFO.

Patent Foramen Ovale (PFO) Closure Devices Market Insights, Competitive Landscape and Market Forecast Report 2017-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Medical devices, Health, Medical specialties, Circulatory system, Cardiovascular system, Cardiology, Foramen ovale, Obstetrics, Pediatrics, PFO, Atrial septal defect

The "Patent Foramen Ovale (PFO) Closure Devices - Market Insights, Competitive Landscape and Market Forecast - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patent Foramen Ovale (PFO) Closure Devices - Market Insights, Competitive Landscape and Market Forecast - 2025" report has been added to ResearchAndMarkets.com's offering.
  • This 'Patent Foramen Ovale (PFO) Closure Devices-Market Insights, Competitive Landscape and Market Forecast-2025' report delivers an in-depth understanding of the patent foramen ovale closure devices, historical and forecasted number of patients eligible for PFO closure as well as the patent foramen ovale closure devices market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • Patent Foramen Ovale Closure Devices: Market Drivers and Barriers
    The report provides insights into the market driving factors that has affected the Patent Foramen Ovale Closure Devices Market such as prevalence of PFO, escalating preferences for minimally-invasive procedures, procedure performed is simple, safer, technically-feasible and effective, less-time consuming.
  • The report helps in developing business strategies by understanding trends shaping and driving the global Patent Foramen Ovale closure devices market.

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Retrieved on: 
Tuesday, June 4, 2019
Congenital heart defects, Medical specialties, Atrial septal defect, Diving medicine, Medicine, Foramen ovale, Foramen secundum, Ostium, ASD

FLAGSTAFF, Ariz., June 4, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs).

Key Points: 
  • FLAGSTAFF, Ariz., June 4, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs).
  • "The FDA approval of the GORE CARDIOFORM ASD Occluder is a significant milestone for innovation in the minimally invasive treatment of ASDs," said Matthew J. Gillespie, M.D., Children's Hospital of Philadelphia, co-principal investigator of the ASSURED Study.
  • The ability to retrieve and reposition the GORE CARDIOFORM ASD Occluder helps me ensure proper positioning and offers me confident closure."
  • In addition to the GORE CARDIOFORM ASD Occluder, the occluder portfolio also includes the GORE CARDIOFORM Septal Occluder which is indicated for ASD closure for defects up to 17 mm and received U.S. Food and Drug Administration approval in 2018 for patent foramen ovale (PFO) closure to prevent recurrent ischemic stroke.